Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 35 | ECE2014 | Next issue

16th European Congress of Endocrinology

Poster Presentations

Bone and Osteoporosis

ea0035p65 | Bone and Osteoporosis | ECE2014

Postpartum osteoporosis with acute evolution: case report

Stoian Dana , Craciunescu Mihaela , Anastasiu Diana , Craina Marius

Objectives: The cases described in the literature, with postpartum and lactation osteoporosis, are very rare.Material: A case report: 28 years old women, that give birth to a 3250 g weight term child, APGAR 10, breast feeding period: 3 months, with acute back pain starting the 2nd months after delivery. On the moment our evaluation she resumed breastfeeding.3 months after delivery she came in our office with diagnosed acut...

ea0035p66 | Bone and Osteoporosis | ECE2014

The investigation of the awareness of bone health in patients with postmenopauosal in the region of Northeastern Anatolia

Akcay Gungor , Gungor Adem

Introduction: The awareness of osteoporosis is essantial of treatment. We investigated the awareness of osteoporosis in the patients with postmenopausal women in the region of Northeastern Anatolia.Methods: Four hundred and two patients with postmenopausal women was included in this study. We detected the age of menopause, the conscience of osteoporosis in the postmenopousal period, DEXA reports, habits of regular walking, drinking of milk, and used to v...

ea0035p67 | Bone and Osteoporosis | ECE2014

Baseline characteristics of Greek patients enrolled in the ExFOS study

Aloumanis Kyriakos , Tzoitou Marianthi , Tsakiri Vassiliki , Bartzis Nikolaos , Drossinos Vangelis , Kapetanos George

Introduction: ExFOS is a multinational, non-interventional, prospective, observational study to evaluate fracture outcomes, back pain, compliance and health-related quality of life in osteoporotic patients treated with teriparatide for up to 24 months. We present the baseline characteristics of the Hellenic subpopulation.Methods: In Greece, 439 consenting patients with osteoporosis (92.3% females), suitable for prescribing teriparatide in the course of n...

ea0035p68 | Bone and Osteoporosis | ECE2014

From EFOS to ExFOS: any news with teriparatide prescription habits in Greece?

Aloumanis Kyriakos , Papaioannou Nikolaos , Dimopoulos Nikolaos , Kioumourtzi Vassiliki , Drossinos Vangelis , Kapetanos George

Purpose: Extended Forsteo Observational Study (ExFOS), a multinational, non-interventional, prospective, observational study to evaluate fracture outcomes, back pain, compliance and health-related quality of life in osteoporotic male and female patients treated with teriparatide (TPTD), has followed European Forsteo Observational Study (EFOS) on postmenopausal women, aiming to provide more data on the effect of the extension of treatment duration from 18 to 24 months and the n...

ea0035p69 | Bone and Osteoporosis | ECE2014

Subclinical celiac disease presented with postpartum low-back pain: case report

Baldane Suleyman , Ipekci Suleyman , Sahin Fatih , Baldane Emine , Karabagli Pinar , Kebapcilar Levent , Kanat Mustafa

Introduction: There are serological findings and mucosal injury similar to the classical form but no gastrointestinal symptoms in subclinical Celiac disease (CD). In this article, we present a case of subclinical CD presented with postpartum low-back pain, in whom we discovered severe lumbar vertebral osteoporosis.Case report: A 35-year-old woman admitted to our outpatient clinic with severe low-back pain. The patient had given birth 5 months ag...

ea0035p70 | Bone and Osteoporosis | ECE2014

Vitamin D receptor (VDR) gene polymorphisms and the risk of low bone mass in type 1 diabetic patients

Dydyshko Yulia , Shepelkevich Alla

Osteoporosis is a common skeletal disease characterized by low bone mass and microarchitectural deterioration with increased susceptibility to fracture. Osteoporosis has a complex etiology and is considered to be a multifactorial polygenic disease. There are more than 150 genes associated with bone mineral density. Our aim was to investigate the frequency of occurrence of vitamin D receptor (VDR) – (FokI, BsmI, ApaI, TaqI) – single nucleotide polymorphisms (SNPs) in ...

ea0035p71 | Bone and Osteoporosis | ECE2014

Bone mineral density in Iranian patients: effects of age, sex, and BMI

Aghaei Mehrdad , Bazrafshan Hamidreza , Qorbani Mostafa , Shojaa Mahdieh , Dashti Hossien Shadpour , Sarmadi Payam , Safari Roya

Introduction: Osteoporosis is a multifactorial skeletal disease that is characterized by reduced bone mineral density (BMD). BMD values depend on several factors such as age, sex and age at menopause. The purpose of this study was to determine the prevalence and changes in BMD in Iranian patients.Methods: Three hundred patients were selected through random sampling technique in 2009. BMD was assessed by Norland machine at the lumbar and femoral neck. Wei...

ea0035p72 | Bone and Osteoporosis | ECE2014

Characteristics of the endocrine osteoporosis

Diyane Khadija , Mghari Ghizlane El , Ansari Nawal El

Introduction: Musculoskeletal manifestations of endocrine disorders are a heterogeneous group of disease, often giving rise to various clinical or radiological individuals. Osteoporosis is a not uncommon complication of endocrine disease. It may even be accompanied by endocrinopathy.Aim of study: Determine mineral bone density profile of patients with endocrinopathy and define the characteristics of osteoporosis and osteopenia in these patients.<p cl...

ea0035p73 | Bone and Osteoporosis | ECE2014

Efficacy of zoledronic acid treatment in Paget disease of bone

Baykan Emine Kartal , Saygili L Fusun , Erdogan Mehmet , Ozgen A Gokhan , Cetinkalp Sevki , Yilmaz Candeger

Purpose: Paget disease is a disease of bone of unknown etiology with increased bone turnover that results in defective bone microarchitecture and bone deformity. Bisphosphonates are used in symptomatic Paget disease of bone. Clinical trials have shown that zoledronic acid was more effective than other bisphosphonates in treatment of Paget disease.Methods: In this study, we retrospectively reviewed the remission and relapse statuses of 12 patients with Pa...

ea0035p74 | Bone and Osteoporosis | ECE2014

The relationship between the existence and degree of coronary atherosclerosis with the level of parathormone

Beypinar Ismail , Oncel Ramazan Can , Ozdem Sebahat , Balci Mustafa Kemal , Sari Ramazan , Altunbas Hasan Ali

Introduction: Parathormone (PTH) is one of the major regulator of the bone and mineral metabolism. Elevated PTH levels in patients with primary and secondary hyperparathyroidism is thought to have negative effects on the cardiovascular system. In our study, we aimed to investigate a possible relationship between plasma PTH levels and coronary atherosclerosis.Methods: Fourty-two men and 35 women, a total of 77 patients were included the study who admitted...

ea0035p75 | Bone and Osteoporosis | ECE2014

What factors influenced on femoral neck bone mineral density in postmenopausal women?

Jedrzejuk Diana , Lwow Felicja , Arkowska Anna , Mieszczanowicz Urszula , Milewicz Andrzej

Postmenopausal osteoporosis is a condition that appears as a result of a sudden reduction in E2 production by the ovaries. The earliest is manifested by the reduction of lumbar BMD; mostly consisted of trabecular bone. Proximal femur is built mostly of cortical bone, and so is aging more slowly, but femoral fracture more often lead to disability and death. The aim of the study was to check which from the anthropometric, hormonal and biochemical markers have the infl...

ea0035p76 | Bone and Osteoporosis | ECE2014

Serum concentration of pentosidine and adipocytokines is related to fragile bone fractures in patients with type 2 diabetes mellitus

Hirano Fuminori , Tsuji Ken , Saito Hiroki , Matsumoto Kakuya , Nishimura Hideo

Fragile bone fractures due to deteriorating bone quality are increased in patients with type 2 diabetes mellitus. This study aimed to measure serum levels of pentosidine and adipocytokines, e.g. adiponectin and leptin, and compare between those biochemical markers and bone mineral density of lumber in patients with type 2 diabetes mellitus. Serum concentration of adiponectin, leptin and pentosidine was measured in 19 type 2 diabetic patients (mean age 65.9+2.3 years) and 13 no...

ea0035p77 | Bone and Osteoporosis | ECE2014

A girl with a hard painful swelling at the right hip: hyperphosphatemic tumeral calcinosis

Soliman Ashraf , Alkhalaf Fawzia , Alhumaidi Noura , Sabt Aml , Bedair Said

Hyperphosphatemic familial tumoral calcinosis (HFTC) is a condition characterized by an increase in the levels of phosphate in the blood (hyperphosphatemia) and abnormal deposits of phosphate and calcium (calcinosis) in in the soft tissue in the periarticular location outside the joint capsule.Case report: This girl presented at the age of 10 years with swelling and pain in the right hip region. On examination a 10×10 cm hard, non-tender swelling wi...

ea0035p78 | Bone and Osteoporosis | ECE2014

Does testosteron have an effect on bone mineral density in postmenopausal women?

Arpaci Dilek , Saglam Fatma , Cuhaci Neslihan , Ersoy Reyhan , Cakir Bekir

Background: Osteoporosis is a common problem in postmenoausal women. There is limited data about the physiological importance of endogenous testosterone on bone mineral density (BMD) in older women is poorly understood.Aim: The aim of this study was to evaluate association of endogeneous testosterone with BMD and BMI.Materials-methods: This cross-sectional study included 64 patients (45–85 year) postmenopausal women; their dem...

ea0035p79 | Bone and Osteoporosis | ECE2014

Renal aspects of primary hyperparathyroidism

Szymczak Jadwiga , Bohdanowicz-Pawlak Anna , Jakubowska Joanna

Introduction: Nephrolithiasis and bone disease are the most common complications of primary hyperparathyroidism (PHPT). The aim of this study was to evaluate the relationships between the existence of kidney stones, renal function and bone mineral density (BMD) in PHPT.Description of methods/design: Biomedical evaluation, BMD measurements and renal ultrasonography were performed in a group of 75 consecutive PHPT patients aged 57.6±12.7 years. The co...

ea0035p80 | Bone and Osteoporosis | ECE2014

1,25-dihydroxyvitamin D3 decreases the proinflammatory interleukin 17 serum levels

Molnar Ildiko , Bohaty llona , Somogyine-Vari Eva

Proinlfammatory cytokines, such as interleukin 17 (IL17) are involved in different inflammatory events causing cardiovascular diseases, osteoporosis and/or infertility. 1,25-dihydroxyvitamin D3 (vitamin D3) plays an immunomodulatory role and therefore, vitamin D3 deficiency can propagate the development of autoimmune diseases, infections and cancers.The effect of vitamin D3 on proinflammatory cytokine levels, s...

ea0035p81 | Bone and Osteoporosis | ECE2014

Factors associated with vertebral fractures in patients with primary hyperparathyroidism

Eller-Vainicher Cristina , Battista Claudia , Guarneri Vito , Palmieri Serena , Salcuni Antonio S , Guglielmi Giuseppe , Corbetta Sabrina , Minisola Salvatore , Spada Anna Maria , Hendy Geoffrey N , Cole David E C , Chiodini Iacopo , Scillitani Alfredo

Introduction: Risk of vertebral fracture (VFx) is in part independent of bone mineral density (BMD) in primary hyperparathyroidism (PHPT). The aim of this study was to examine whether other factors, including the genotype of common polymorphisms in the calcium-sensing receptor (CASR) gene, are associated with VFx.Patients and methods: In 266 Caucasian PHPT patients, serum calcium, phosphate, creatinine, total alkaline phosphatase, intact PTH, 25-hydroxyv...

ea0035p82 | Bone and Osteoporosis | ECE2014

Structure of bone disease the different clinical forms of primary hyperparathyroidism

Brutskaya-Stempkovskaya Elena , Shepelkevich Alla , Holodova Elena

Introduction: The main pathogenic mechanism of bone development disease in primary hyperparathyroidism (PHPT) is speeding bone resorbtion over bone formation rate.Objective: Studying the features of bone disease in different clinical variants of PHPT.Materials and methods: We have studied 114 patients with PGPT (average age 52.19) a general medical examination has been made. The questionnaire perfomed (with the estimate of anamnest...

ea0035p83 | Bone and Osteoporosis | ECE2014

Low-carbohydrate/high-fat diets do not have negative effects on bone density in female rats in contrast to male rats

Zengin Ayse , Kropp Benedikt , Chevalier Yan , Horngacher Amon , Sustarsic Riia , Sustarsic Elahu , Benedix Sarina , Herbach Nadja , Milz Stefan , Bielohuby Maximilian , Bidlingmaier Martin

Ketogenic low-carbohydrate/high fat diets (LC-HFD) induce weight loss in both animals and humans. However, a number of unwanted side effects with these diets have been reported. We have previously shown in male rats that LC-HFDs negatively affect bone growth and bone mineral density, possibly due to macronutrient-induced impairments of the GH/IGF-system. Given the importance of dietary macronutrients in the regulation of bone density in male rats, in this study we investigated...

ea0035p84 | Bone and Osteoporosis | ECE2014

Teriparatide treatment in a patient with severe pregnancy related osteoporosis

Polat Burcak , Evranos Berna , Aydin Cevdet , Ersoy Reyhan , Cakir Bekir

Introduction: Pregnancy or lactation related osteoporosis (PLO) is very rare. It usually occurs in the third trimester or in the early post partum period and manifestations are severe back pain and loss of height due to vertebral fractures. Its etiology is not well understood. Classical treatment is cessation of lactation, calcium and Vit-D supplementation and biphosphanates in chosen cases. All osteoporosis drugs are approved mainly for post-menouposal osteoporosis a...

ea0035p85 | Bone and Osteoporosis | ECE2014

The total fat mass and the fracture risk assessment: a study in 146 Romanian menopausal women

Carsote Mara , Radoi Valentin , Mihai Alexandra , Geleriu Andreea , Miulescu Rucsandra Danciulescu , Capatana Cristina , Trifanescu Raluca , Poiana Catalina

Introduction: The fat mass (FM) is assessed by DXA, magnetic resonance, etc. One of the most accessible methods for current practice is bioimpedance.Aim: We analyzed FM based on bioimpedance and fragility fracture risk.Material and method: This is a transversal study in women, admitted at C.I.Parhon National Institute of Endocrinology, Bucharest, Romania. The inclusion criteria were women in menopause. The exclusion criteria were p...

ea0035p86 | Bone and Osteoporosis | ECE2014

The 10-year absolute fracture risk and central DXA correlations in 505 Romanian menopausal women

Carsote Mara , Radoi Valentin , Mihai Alexandra , Geleriu Andreea , Baciu Ionela , Capatana Cristina , Paun Diana , Poiana Catalina

Introduction: The new tool FRAX indicated risk of fracture, using or not DXA which is the golden standard for osteoporosis diagnosis.Aim: We analyzed the lumbar DXA correlations with 10-year fragility fracture risk probability.Material and method: A cross sectional study in postmenopausal women was designed. They were osteoporosis free at baseline; none of them has previously been treated for osteoporosis. The anamnesis, the anthro...

ea0035p87 | Bone and Osteoporosis | ECE2014

Bone mineral density, bone turnover and vitamin D status in women with diabetes mellitus type 2 and healthy women with osteoporosis in menopause

Novakovic-Paro Jovanka , Bajkin Ivana , Tomic-Naglic Dragana , Mitrovic Milena , Icin Tijana , Vukovic Bojan , Pejin Radoslav , Popovic Djordje , Medic-Stojanoska Milica , Kovacev-Zavisic Branka

Introduction: Literature data suggests increased fracture risk in women with diabetes mellitus type 2 but the underlying mechanism is not fully understood.Aim of the study was to analyse bone turnover parameters in women with DM2 and in healthy women with osteoporosis in menopause.Materials and methods: There were 76 participants out of wich 36 women with DM2. Average diabetes duration was 14.48±10.51 years with mean HbA1c 7.8...

ea0035p88 | Bone and Osteoporosis | ECE2014

The −857C/T single-nucleotide polymorphism of TNFα gene is associated with bone mineral density in Greek peri- and postmenopausal women

Markatseli Anastasia , Lazaros Leandros , Markoula Sofia , Tigas Stelios , Georgiou Ioannis , Tsatsoulis Agathocles

Introduction: The cytokine tumor necrosis factor alpha (TNFα) is encoded by the TNFα gene and stimulates bone resorption. TNFα is involved in the pathogenesis of bone loss associated with estrogen deficiency. Polymorphisms in the TNFα gene have been associated with bone mineral density (BMD) in different populations.Objectives: The present study aimed to explore the influence of the single-nucleotide polymorphism <em...

ea0035p89 | Bone and Osteoporosis | ECE2014

State of bone metabolism in patients with urolithiasis

Peretokina Elena , Mokrysheva Natalia , Egshatyn Lilit , Dzeranov Nikolay

Much attention is attracted increased risk of fractures in patients with urolithiasis. Study the possible relationship of pathophysiological mechanisms of osteoporosis/osteopenia and nephrolithiasis.Objective: To assess the state of bone metabolism, vitamin D level in patients with urolithiasis compared with healthy individuals.Methods: Were examined 58 patients with nephrolithiasis (36 women, and 22 men) and 20 healthy individuals...

ea0035p90 | Bone and Osteoporosis | ECE2014

Familial hypocalciuric hypercalcemia: an important differential diagnosis from hyperparathyroidism

Luque-Fernandez Ines , Vicente Almudena , Luque Alessandra , Del Val Florentino , Garin Intza , Morlan Miguel Angel

Introduction: Familial hypocalciuric hypercalcemia (FHH) is a rare, benign, autosomal dominant condition usually caused by heterozygous inactivating mutations in the gene encoding the calcium sensing receptor (CASR).Case: 22-year-old woman referred to endocrinology for suspected polycystic ovary syndrome. Hypercalcemia is detected. Laboratory tests showed persistent hypercalcemia with a serum total calcium of 11.1 mg/dl (8.8–10.2), phosphorus 2.8, i...

ea0035p91 | Bone and Osteoporosis | ECE2014

Usefulness of serum sclerostin as a diagnostic marker of osteoporosis in a cohort of spanish postmenopausal women

Luque-Fernandez Ines , Garcia-Martin Antonia , Reyes-Garcia Rebeca , Morales-Santana Sonia , Garcia-Fontana Beatriz , Munoz-Torres Manuel

Introduction: Sclerostin, produced by osteocytes, is a potent inhibitor of Wnt signaling and bone formation. The usefulness of its determination in clinical practice is not well established.Objectives: The aims of this study were to evaluate serum sclerostin levels in a cohort of Spanish posmenopausal women, and to analyze its relationship with bone metabolism.Methods: We measured serum sclerostin in 97 posmenopausal women using EL...

ea0035p92 | Bone and Osteoporosis | ECE2014

Increased osteoporotic fractures' risk in elderly patients with lower sodium levels

Trifanescu Raluca , Carsote Mara , Soare Dan , Poiana Catalina

Background: Low serum sodium levels were associated both in experimental studies and in clinical practice with increased prevalence of osteoporosis, due to decreased bone mineralization and increased osteoclastic activity. On the other hand, hyponatremia – independent of osteoporosis – is associated with fracture occurrence.Objectives: To assess the relationship between serum sodium levels and osteoporotic fractures.Patie...

ea0035p93 | Bone and Osteoporosis | ECE2014

The effects of recombinant human TSH on selected bone markers in the follow-up of patients treated for differentiated thyroid carcinoma

Krawczyk-Rusiecka Kinga , Skowronska-Jozwiak Elzbieta , Wojciechowska-Durczynska Katarzyna , Glowacka Ewa , Lewinski Andrzej

Introduction: TSH seems to play direct role in bone metabolism. TSH receptors are expressed on osteoblasts and osteoclast precursors. Osteocalcin (OC) is well known marker of bone formation, whereas collagen type I crosslinked C-telopeptide I (CTX) is marker of bone resorption. Sclerostin is a protein, recently found to inhibit bone formation, while parathormone (PTH) inhibits sclerostin production. The aim of the study was to estimate sclerostin, OC, CTX and PTH levels after ...

ea0035p94 | Bone and Osteoporosis | ECE2014

Influence of osteoporosis risk factors on extensive suppression of bone metabolism during antiresorptive therapy

Icin Tijana , Novakovic-Paro Jovanka , Vukovic Bojan , Bajkin Ivana , Medic-Stojanoska Milica

Introduction: Some patients develop excessive bone metabolism supression during antiresorptive therapy. Low remodelling rate enables increase in tissue mineralisation density and homogenicity of bone trabeculae. Increase in density makes micro-damage more likely. Increased homogenicity provides less resistance to spread of the micro-cracks and slowed remodelling slows down removal of microdemage. All this leads to increased bone fragility.Aim: To establi...

ea0035p95 | Bone and Osteoporosis | ECE2014

Osteoporosis in young male secondary to cancer treatment: case report

Simoes-Pereira Joana , Silva-Vieira Margarida , Pereira Maria Conceicao

Introduction: Children undergoing treatment for cancer are prone to several long-term endocrine complications, which can permanently affect bone tissue.Case report: A 25-year-old man was diagnosed with right maxillary sinus rhabdomyosarcoma at the age of 5. He was submitted to chemotherapy – intrathecal methotrexate+prednisolone and i.v. vincristine+actinomycin+ifosfamide – and submaxillary+cervical radiotherapy, 60Gy. At the age of 12, he was ...

ea0035p96 | Bone and Osteoporosis | ECE2014

Jaw osteonecrosis in a patient with postmenopausal osteoporosis on antiresorptive treatment

Kostoglou-Athanassiou Ifigenia , Athanassiou Panagiotis , Xanthakou Eleni , Kaldrymides Philippos

: Postmenopausal osteoporosis is a common condition affecting many women. Management of postmenopausal osteoporosis involves the administration of vitamin D, calcium and antiresorptive agents. The long-term management of postmenopausal osteoporosis with antiresorptive agents may present some dangers and adverse effects such as bone necrosis or atypical bone fractures.Case report: The aim was to describe the case of a female patient with postmenopausal ...

ea0035p97 | Bone and Osteoporosis | ECE2014

Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells after treatment with hormonal replacement therapy and tibolone in patients after menopause with osteopenia or postmenopausal osteoporosis

Stuss Michal , Ceglowska Agnieszka , Rieske Piotr , Stepien-Klos Wioletta , Liberski Pawel , Sewerynek Ewa

The aim of the reported study was to assess gene expression levels of the OPG/RANK/RANKL system in peripheral blood mononuclear cells (PBMC) after tibolone and hormonal replacement therapy (HRT) administered to patients with oestrogen deficiency symptoms and osteopenia or postmenopausal osteoporosis.Material and methods: 74 women after menopause, aged 45–71 years, were enrolled into the study and randomly assigned to different medical therapies: HRT...

ea0035p98 | Bone and Osteoporosis | ECE2014

Assessment of OPG and RANKL serum levels after treatment with hormonal replacement therapy and tibolone in patients after menopause with osteopenia or postmenopausal osteoporosis

Stuss Michal , Ceglowska Agnieszka , Rieske Piotr , Stepien-Klos Wioletta , Liberski Pawel , Sewerynek Ewa

The aim of this study was to evaluate quantitative changes in OPG and RANKL proteins after tibolone and hormonal replacement therapy (HRT) administered to patients with oestrogen deficiency symptoms and osteopenia or postmenopausal osteoporosis.Material and methods: A total of 74 women after menopause, aged 45–71 years, patients of the Outpatient Clinic of Osteoporosis of the Military Teaching Hospital in Lodz, were enrolled into the study. The pati...

ea0035p99 | Bone and Osteoporosis | ECE2014

Effect of estroprogestagen treatment on bone mineral density and concentration of osteoprotegerin in girls with Turner syndrome

Sowinska-Przepiera Elzbieta , Andrysiak-Mamos Elzbieta , Walkowiak Aleksandra , Rudnicka Marta , Osowicz-Korolonek Lilianna , Syrenicz Anhelli

Background: Osteoprotegerin (OPG), a component of the RANKL/RANK/OPG pathway, can inhibit bone resorption by affecting osteoclastogenesis. Estrogens deficiency is associated with decreased expression of OPG and increased osteoclast activity, and thus can lead to disorders of bone remodeling.Objective: To analyze relationship between serum OPG and bone mineral density (BMD) in patients with Turner syndrome (TS) subjected to estroprogestagen (EP) treatment...

ea0035p100 | Bone and Osteoporosis | ECE2014

Bone mineral density in girls with functional hypothalamic amenorrhea subjected to estroprogestagen treatment: a 4-year prospective study

Sowinska-Przepiera Elzbieta , Andrysiak-Mamos Elzbieta , Kazmierczyk-Puchalska Agnieszka , Wentland-Kotwicka Ewa , Syrenicz Anhelli

Introduction/objective: To evaluate the effects of estroprogestagen therapy (EP) on the mineral bone density (BMD) of girls with functional hypothalamic amenorrhea (FHA).Design: Prospective observation of 78 FHA girls subjected to 4-year EP therapy (Group A) and 50 controls (Group C).Methods: Anthropometric measurements (height, body weight) were taken for all participants along with baseline values of hormonal parameters and bone ...